Takeda adds 18-month data to case for Dengue vaccine approval

TAK-003, the dengue vaccine candidate from Japanese drugmaker Takeda (TYO: 4502), is now backed by 18-month Phase III trial results. These build upon the 12-month data from the TIDES trial, which met its primary endpoint of demonstrating protection"...